Roche said that its cancer immunotherapy Tecentriq (atezolizumab) in combination with chemotherapy as first-line of treatment improved survival of patients with advanced non-squamous non-small cell lung cancer (NSCLC) in a phase 3 trial.
Original Article: Roche’s Tecentriq-chemo combo extends survival in phase 3 NSCLC trial